Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0014547 (
focal epilepsy
)
1,627
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Objective:
Focal epilepsy
is the most common subtype of epilepsies in which the influence of underlying genetic factors is emerging but remains largely uncharacterized. The purpose of this study is to determine the contribution of currently known disease-causing genes in a large cohort (
n
= 593) of common focal non-lesional epilepsy patients.
Methods:
The customized
focal epilepsy
gene panel (21 genes) was based on multiplex polymerase chain reaction (PCR) and sequenced by Illumina MiSeq platform.
Results:
Eleven variants (1.85%) were considered as pathogenic or likely pathogenic, including seven novel mutations. There were three
SCN1A
(p.Leu890Pro, p.Arg1636Ter, and p.Met1714Val), three
PRRT2
(two p.Arg217Profs
*
8 and p.Leu298Pro), two
CHRNA4
(p.Ser284Leu, p.Ile321Asn), one
DEPDC5
(p.Val516Ter)
, one PCDH19
(p.Asp233Asn), and one
SLC2A1
(p.Ser414Ter) variants. Additionally, 16 other rare variants were classified as unknown significance due to inconsistent phenotype or lack of segregation data.
Conclusion:
Currently known
focal epilepsy
genes only explained a very small subset of
focal epilepsy
patients. This indicates that the underlying genetic architecture of focal epilepsies is very heterogeneous and more novel genes are likely to be discovered. Our study highlights the usefulness, challenges and limitations of using the multi-gene panel as a diagnostic test in routine clinical practice in patients with
focal epilepsy
.
...
PMID:Molecular Genetic Characterization of Patients With Focal Epilepsy Using a Customized Targeted Resequencing Gene Panel. 3003 62